Abstract
The predictive value of expression of p16INK4A, retinoblastoma (Rb) and p53 proteins for prognosis was evaluated in 76 patients with non-small-cell lung cancers (NSCLCs) that were potentially curatively resected between 1990 and 1995, using the results of immunostaining analyses of these proteins as reported in our previous study (Kinoshita et al, 1996). Of these NSCLCs, 22 (29%) lacked p16 protein expression and eight (11%) Rb protein, while 30 (39%) showed positive (altered) p53 protein expression. Survival of patients with p16-negative tumours was not significantly different from that of patients with p16-positive tumours (5-year survival rates 67% and 72% respectively, P = 0.8), nor was survival of patients with Rb-negative tumours significantly different from that of patients with Rb-positive tumours (5-year survival rates 42% and 69% respectively, P = 0.9). Moreover, survival of patients with p16/Rb-negative (either p16- or Rb-negative) tumours was not significantly different from that of patients with p16/Rb-positive (both p16- and Rb-positive) tumours (5-year survival rates 67% and 68% respectively, P = 0.7). In contrast, survival of patients with p53-positive (altered) tumours tended to be shorter than that of patients with p53-negative (unaltered) tumours (5-year survival rates 56% and 78% respectively, P = 0.06). In univariate analysis of potential prognostic factors, p16, Rb and p16/Rb proteins were not significant prognostic factors in the present cohort of potentially curatively resected NSCLCs. Altered p53 protein status tended to be a negative prognostic factor (P = 0.06 by the univariate analysis). These results indicate that loss of p16 protein alone, or in combination with loss of Rb protein, does not predict the clinical outcome of patients with resected NSCLCs.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Beahrs, OH, Henson, DE, Hutter, RVP & Kennedy, BJ (1992) Lung. In: Manual for Staging of Cancer, 4th edn. 115–122, American Joint Committee on Cancer: Chicago
Betticher, DC, White, GRM, Liu, X, Kappeler, A, Altermatt, HJ, Thatcher, N & Heighway, J (1997) G1 control gene status is frequently altered in resectable non-small-cell lung cancer. Int J Cancer (Pred Oncol) 74: 556–562
Cairns, P, Mao, L, Merlo, A, Lee, DJ, Schwab, D, Eby, Y, Tokino, K, van der Riet, P, Blaugrund, JE & Sidransky, D (1994) Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 265: 415–417
Dosaka-Akita, H, Shindoh, M, Fujino, M, Kinoshita, I, Akie, K, Katoh, M & Kawakami, Y (1994) Abnormal p53 expression in human lung cancer is associated with histologic subtypes and patient smoking history. Am J Clin Pathol 102: 660–664
Dosaka-Akita, H, Hu, SX, Fujino, M, Harada, M, Kinoshita, I, Xu, HJ, Kuzumaki, N, Kawakami, Y & Benedict, WF (1997) Altered retinoblastoma protein expression in nonsmall cell lung cancer. Cancer 79: 1329–1337
Fujino, M, Dosaka-Akita, H, Harada, M, Hiroumi, H, Kinoshita, I, Akie, K & Kawakami, Y (1995) Prognostic significance of p53 and ras p21 expression in nonsmall cell lung cancer. Cancer 76: 2457–2463
Gehan, EA (1965) A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika 52: 203–223
Geradts, J, Kratzke, RA, Niehans, GA & Lincoln, CE (1995) Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression. Cancer Res 55: 6006–6011
Hannon, GJ & Beach, D (1994) p15INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature (Lond) 371: 257–261
Harrell, FE Jr (1986) The PHGLM procedure. In: Supplementary Library User’s Guide, Hastings RP (ed.), pp, 437–466, SAS Institute: Cary, NC
Hayashi, N, Sugimoto, Y, Tsuchiya, E, Ogawa, M & Nakamura, Y (1994) Somatic mutations of the MTS (multiple tumor suppressor) 1/CDK4I (cyclin-dependent kinase-4 inhibitor) gene in human primary non-small-cell lung carcinomas. Biochem Biophys Res Commun 202: 1426–1430
Horio, Y, Takahashi, T, Kuroishi, T, Hibi, K, Suyama, M, Niimi, T, Shimokata, K, Yamakawa, K, Nakamura, Y, Ueda, R & Takahashi, T (1993) Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res 53: 1–4
Kaplan, EL & Meier, P (1958) Nonparametric estimation for incomplete observations. J Am Stat Assoc 53: 457–481
Kelley, MJ, Nakagawa, K, Steinberg, SM, Mulshine, JL, Kamb, A & Johnson, BE (1995) Differential inactivation of CDKN2 and Rb protein in non-small-cell and small-cell lung cancer cell lines. J Natl Cancer Inst 87: 756–761
Kinoshita, I, Dosaka-Akita, H, Mishina, T, Akie, K, Nishi, M, Hiroumi, H, Hommura, F & Kawakami, Y (1996) Altered p16INK4 and retinoblastoma protein status in non-small cell lung cancer: potential synergistic effect with altered p53 protein on proliferative activity. Cancer Res 56: 5557–5562
Kratzke, RA, Greatens, TM, Rubins, JB, Maddaus, MA, Niewoehner, DE, Niehans, GA & Geradts, J (1996) Rb and p16INK4a expression in resected non-small cell lung tumors. Cancer Res 56: 3415–3420
Lukas, J, Parry, D, Aagaard, L, Mann, DJ, Bartkova, J, Strauss, M, Peters, G & Bartek, J (1995) Retinoblastoma protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature (Lond) 375: 503–506
Minna, JD, Sekido, Y, Fong, KM & Gazdar, AF (1997) Molecular biology of lung cancer. In: Cancer: Principles & Practice of Oncology, 5th edn, DeVita VT Jr, Hellman S, Steven A (eds), pp, 849–857, Lippincott: Philadelphia
Mitsudomi, T, Oyama, T, Kusano, T, Osaki, T, Nakanishi, R & Shirakusa, T (1993) Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer. J Natl Cancer Inst 85: 2018–2023
Moore, DF Jr & Lee, JS (1996) Staging and prognostic factors: non-small cell lung cancer. In: Lung Cancer: Principles and Practice, Pass HI Mitchell JB Johnson DH Turrisi AT (eds), pp. 481–494, Lippincott: Philadelphia
Nakagawa, K, Conrad, NK, Williams, JP, Johnson, BE & Kelley, MJ (1995) Mechanism of inactivation of CDKN2 and MTS2 in non-small-cell lung cancer and association with advanced stage. Oncogene 11: 1843–1851
Nishio, M, Koshikawa, T, Kuroishi, T, Suyama, M, Uchida, K, Takagi, Y, Washimi, O, Sugiura, T, Ariyoshi, Y, Takahashi, T, Ueda, R & Takahashi, T (1996) Prognostic significance of abnormal p53 accumulation in primary, resected non-small-cell lung cancers. J Clin Oncol 14: 497–502
Nishio, M, Koshikawa, T, Yatabe, Y, Kuroishi, T, Suyama, M, Nagatake, M, Sugiura, T, Ariyoshi, Y, Mitsudomi, T, Takahashi, T & Takahashi, T (1997) Prognostic significance of cyclin D1 and retinoblastoma expression in combination with p53 abnormalities in primary, resected non-small-cell lung cancers. Clin Cancer Res 3: 1051–1058
Okamoto, A, Demetrick, DJ, Spillare, EA, Hagiwara, K, Hussain, SP, Bennett, WP, Forrester, K, Gerwin, B, Serrano, M, Beach, DH & Harris, CC (1994) Mutations and altered expression of p16INK4 in human cancer. Proc Natl Acad Sci USA 91: 11045–11049
Okamoto, A, Hussain, SP, Hagiwara, K, Spillare, EA, Rusin, MR, Demetrick, DJ, Serrano, M, Hannon, GJ, Shiseki, M, Zariwala, M, Xiong, Y, Beach, DH, Yokota, J & Harris, CC (1995) Mutations in the p16 INK4/MTS1/CDKN2, p15INK4B /MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res 55: 1448–1451
Otterson, GA, Kratzke, RA, Coxon, A, Kim, YW & Kaye, FJ (1994) Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene 9: 3375–3378
Otterson, GA, Khleif, SN, Chen, W, Coxon, AB & Kaye, FJ (1995) CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5-aza 2´deoxycytidine. Oncogene 11: 1211–1216
Quinlan, DC, Davidson, AG, Summers, CL, Warden, HE & Doshi, HM (1992) Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 52: 4828–4831
Serrano, M, Hannon, GJ & Beach, D (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (Lond) 366: 704–707
Shapiro, GI, Edwards, CD, Kobzik, L, Godleski, J, Richards, W, Sugarbaker, DJ & Rollins, BJ (1995) Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. Cancer Res 55: 505–509
Taga, S, Osaki, T, Ohgami, A, Imoto, H, Yoshimatsu, T, Yoshino, I, Yano, K, Nakanishi, R, Ichiyoshi, Y & Yasumoto, K (1997) Prognostic value of the immunohistochemical detection of p16INK4 expression in nonsmall cell lung carcinoma. Cancer 80: 389–395
Tam, SW, Shay, JW & Pagano, M (1994) Differential expression and cell cycle regulation of the cyclin-dependent kinase 4 inhibitor p16Ink4. Cancer Res 54: 5816–5820
WHO (1982) Histological Typing of Lung Tumours, 2nd edition. Am J Clin Pathol 77: 123–136
Xu, HJ, Cagle, PT, Hu, SX, Li, J & Benedict, WF (1996) Altered retinoblastoma and p53 protein status in non-small-cell carcinoma of the lung: potential synergistic effects on prognosis. Clin Cancer Res 2: 1169–1176
Xu, H, Hu, S & Benedict, WF (1991a) Lack of nuclear RB protein staining in G0/middle G1 cells: correlation to changes in total RB protein level. Oncogene 6: 1139–1146
Xu, HJ, Hu, SX, Cagle, PT, Moore, GE & Benedict, WF (1991b) Absence of retinoblastoma protein expression in primary non-small cell lung carcinomas. Cancer Res 51: 2735–2739
Xu, HJ, Quinlan, DC, Davidson, AG, Hu, SX, Summers, CL, Li, J & Benedict, WF (1994) Altered retinoblastoma protein expression and prognosis in early-stage non-small-cell lung carcinoma. J Natl Cancer Inst 86: 695–699
Yatabe, Y, Masuda, A, Koshikawa, T, Nakamura, S, Kuroishi, T, Osada, H, Takahashi, T, Mitsudomi, T & Takahashi, T (1998) p27KIP1 in human lung cancers: differential changes in small cell and non-small cell carcinomas. Cancer Res 58: 1042–1047
Zhang, X, Xu, HJ, Murakami, Y, Sachse, R, Yashima, K, Hirohashi, S, Hu, SX, Benedict, WF & Sekiya, T (1994) Deletions of chromosome 13q, mutations in retinoblastoma 1, and retinoblastoma protein state in human hepatocellular carcinoma. Cancer Res 54: 4177–4182
Author information
Authors and Affiliations
Additional information
Correspondence to: H Dosaka-Akita
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Hommura, F., Dosaka-Akita, H., Kinoshita, I. et al. Predictive value of expression of p16INK4A, retinoblastoma and p53 proteins for the prognosis of non-small-cell lung cancers. Br J Cancer 81, 696–701 (1999). https://doi.org/10.1038/sj.bjc.6690750
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690750
Keywords
This article is cited by
-
Molecular interaction studies of Deguelin and its derivatives with Cyclin D1 and Cyclin E in cancer cell signaling pathway: The computational approach
Scientific Reports (2019)
-
Relationship of immunohistochemical biomarker expression and lymph node involvement in patients undergoing surgical treatment of NSCLC with long-term follow-up
Tumor Biology (2014)
-
RB family members as predictive and prognostic factors in human cancer
Oncogene (2006)